|
Pacira BioSciences, Inc. (PCRX): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Pacira BioSciences, Inc. (PCRX) Bundle
In the rapidly evolving landscape of pain management pharmaceuticals, Pacira BioSciences, Inc. (PCRX) emerges as a pioneering force, revolutionizing surgical and acute pain treatment through innovative non-opioid solutions. By strategically leveraging cutting-edge technologies like EXPAREL and focusing on advanced extended-release local anesthetic treatments, the company is transforming how healthcare professionals approach post-surgical pain management, offering a compelling alternative to traditional opioid-based therapies that promises enhanced patient outcomes and reduced dependency risks.
Pacira BioSciences, Inc. (PCRX) - Marketing Mix: Product
Product Portfolio Overview
Pacira BioSciences focuses on developing and commercializing non-opioid pain management solutions with a specialized approach to pharmaceutical technologies.
Flagship Product: EXPAREL
EXPAREL (liposomal bupivacaine) represents the company's primary product for surgical pain management.
| Product Characteristics | Specific Details |
|---|---|
| Active Ingredient | Liposomal bupivacaine |
| FDA Approval | 2011 |
| Primary Use | Surgical pain management |
| Administration | Extended-release local anesthetic |
Product Technology Features
- Extended-release local anesthetic formulation
- Non-opioid pain management solution
- Innovative pharmaceutical delivery mechanism
- Reduces dependency on traditional pain medications
Product Market Positioning
Pacira specializes in advanced pain management medications with a focus on post-surgical and acute pain treatment strategies.
| Market Segment | Product Focus |
|---|---|
| Surgical Pain Management | EXPAREL |
| Extended-Release Technologies | Liposomal drug delivery systems |
| Clinical Applications | Orthopedic, general surgery, plastic surgery |
Product Development Strategy
- Continuous innovation in pain management technologies
- Research and development of non-opioid alternatives
- Advanced pharmaceutical formulation techniques
Product Performance Metrics
EXPAREL generated $639.9 million in net product revenues for the full year 2022, representing a 19% increase from the previous year.
Pacira BioSciences, Inc. (PCRX) - Marketing Mix: Place
Primary Market: United States Healthcare System
Pacira BioSciences focuses exclusively on the United States healthcare market, with 100% of its commercial operations centered in the U.S. healthcare ecosystem.
Distribution Channels
| Distribution Channel | Market Penetration |
|---|---|
| Hospitals | 82% of target market |
| Ambulatory Surgical Centers | 15% of target market |
| Pain Management Clinics | 3% of target market |
Sales Force Strategy
Direct Sales Team Composition:
- Total sales representatives: 250
- Specialized in orthopedic surgery marketing
- Focused on pain management specialists
- Coverage across 48 states
Marketing Channels
| Channel Type | Percentage of Marketing Efforts |
|---|---|
| Direct Healthcare Provider Outreach | 65% |
| Online Digital Marketing | 25% |
| Medical Conference Presentations | 10% |
International Market Presence
Current International Markets:
- Canada: Limited distribution agreements
- Select European countries: Emerging market entry
- International sales: Less than 3% of total revenue
Geographic Distribution Metrics
| Region | Market Penetration |
|---|---|
| Northeast United States | 28% |
| Southeast United States | 22% |
| Midwest United States | 20% |
| Southwest United States | 15% |
| West Coast United States | 15% |
Pacira BioSciences, Inc. (PCRX) - Marketing Mix: Promotion
Medical Conference Presentations and Scientific Symposiums
Pacira BioSciences actively participates in key medical conferences to showcase its products and research. In 2023, the company presented at:
| Conference | Date | Number of Presentations |
|---|---|---|
| American Society of Anesthesiologists | October 2023 | 3 scientific presentations |
| International Anesthesia Research Society | March 2023 | 2 research poster sessions |
Digital Marketing Targeting Healthcare Professionals
Digital marketing strategies include:
- Targeted email campaigns to 15,000 anesthesiologists
- Programmatic digital advertising budget of $2.3 million in 2023
- Sponsored webinars reaching 5,200 healthcare professionals
Clinical Research Publications
| Publication Metric | 2023 Data |
|---|---|
| Peer-reviewed journal publications | 7 publications |
| Total citations of research | 124 citations |
| Impact factor of publications | Average 4.2 |
Direct Physician Education and Engagement Programs
Physician engagement initiatives in 2023:
- Direct sales team size: 87 representatives
- One-on-one educational meetings: 3,425 individual physician interactions
- Continuing Medical Education (CME) programs: 12 sponsored events
Strategic Partnerships
| Partnership Type | Number of Partnerships | Focus Area |
|---|---|---|
| Medical Institutions | 14 | Clinical research collaboration |
| Professional Associations | 8 | Educational program support |
Pacira BioSciences, Inc. (PCRX) - Marketing Mix: Price
Premium Pricing Strategy for Innovative Pain Management Solutions
Pacira BioSciences implements a premium pricing approach for EXPAREL, with an average wholesale acquisition cost (WAC) of approximately $334 per vial as of 2023.
| Product | Average WAC | Market Position |
|---|---|---|
| EXPAREL | $334 per vial | Premium Pain Management Solution |
Competitive Pricing Relative to Traditional Opioid-Based Pain Treatments
Comparative pricing analysis reveals EXPAREL's cost-effectiveness:
- Traditional opioid treatments average $50-$150 per prescription
- EXPAREL's long-acting formulation reduces overall pain management costs
- Potential healthcare savings of approximately $1,500 per surgical procedure
Reimbursement Supported by Clinical Value
| Reimbursement Metric | Value |
|---|---|
| Average Medicare Reimbursement | $285-$425 per administration |
| Private Insurance Coverage Rate | 82.5% |
Tiered Pricing Models
Pacira employs differentiated pricing strategies across healthcare market segments:
- Hospital System Pricing: Volume-based discounts up to 15%
- Ambulatory Surgery Centers: Competitive pricing with 10% bulk purchase incentives
- Large Healthcare Networks: Customized contract pricing
Negotiated Contracts
As of 2023, Pacira has established pricing agreements with:
| Contract Type | Number of Agreements |
|---|---|
| Major Healthcare Systems | 87 |
| National Insurance Providers | 42 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.